More results from the RECOVERY trial - Hydroxychloroquine:
Among patients hospitalised with COVID-19, hydroxychloroquine (HCQ) did not improve 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death
1561 patients were randomised to HCQ + usual care
3155 patients were randomised to usual care alone
in the largest randomised trial of HCQ for treatment of COVID
No evidence of benefit of HCQ on any of the pre-specified endpoints.
In patients admitted to hospital with COVID-19, lopinavir–ritonavir did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.
Lopinavir-ritonavir is an HIV treatment that was widely recommended and used for #COVID19. The RECOVERY trial has shown it does not work - so doctors no longer use it.
That’s why we do trials - to separate out drugs we think might work from drugs we know do work.